Company intelligence / Profile preview
Galapagos NV
Mechelen, N/A, Belgiumglpg.com ↗
- Ownership
- Public · GLPG
- Employees
- ~725
- Development stage
- Commercial
01
Overview
The company is currently focusing on cell therapy in oncology and has announced plans to separate into two entities. They are seeking partners for their small molecule assets, including the TYK2 inhibitor GLPG3667 which is in Phase 2 for systemic lupus erythematosus and dermatomyositis.
- Therapeutic areas
- GastroenterologyPulmonologyRheumatologyImmunologyDermatologyOncologyRare Diseases
- Modalities
- Small MoleculesCell Therapy (CAR-T)Biologics
- Industry
- Biotech
02
Drug pipeline
34 assets33 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Galapagos NV.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galapagos NV.